Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

Faculty of Health Sciences

Idiopathic pulmonary fibrosis: Nintedanib

The effects, mechanism of action and clinical trials for nintedanib as a treatment for IPF.

Nintedanib is an approved pharmacological agent for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This video explains the effects, mechanism of action and clinical trials for nintedanib.

[Please complete our feedback form]

 Demystifying Medicine,  Education,  Idiopathic pulmonary fibrosis (IPF)

Related News

News Listing

Three people in a lab, gathered around a microscope, in black and white.

Department of Medicine  ➚

Pain to progress: An impactful history of lupus research and care at McMaster

Collaborations & Partnerships, Education, Research

December 20, 2024

A headshot of Geoffrey Norman. He is wearing a purple dress shirt and is smiling for the photo.

Professor emeritus Geoffrey Norman’s generous gift establishes new lecture series in education research

Education

December 16, 2024

Firas Khalid smiles confidently indoors, wearing a white shirt, black blazer, and tie.

HEI  ➚

Health Policy PhD grad’s journey from valedictorian to federal policy advisor

Education

December 10, 2024